Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes
Date
2009-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Saudi Med J
Abstract
Objectives: To examined whether serum paraoxonase (PON1) and arylesterase (ARE) activities are correlated with inflammatory biomarkers (procalcitonin and high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS).
Methods: This cross-sectional study was conducted at the Departments of Cardiology and Biochemistry, Uludag University School of Medicine, Bursa, Turkey, from April 2007 to December 2007. Seventy-eight consecutive patients with ACS and 39 healthy controls were investigated. Acute coronary syndrome patients were divided into 3 groups according to their clinical presentation: unstable angina pectoris (UAP) (Braunwald III-B, n=25), non-ST elevation myocardial infarction (NSTEMI) (n=18), and ST-elevation myocardial infarction (STEMI) (n=35). Serum PON1/ARE activities were measured spectrophotometrically. Levels of procalcitonin and hs-CRP were measured by immunoassay.
Results: Paraoxonase/ARE activities were significantly lower in all patient groups compared to controls. No correlation between PON1/ARE activities and high-density-cholesterol levels was seen. Among ACS patients, serum ARE activity correlated inversely with baseline and 48-hour procalcitonin (r=-0.577, p=0.009, and r=-0.642, p=0.019) and hs-CRP levels (r=-0.614, p=0.03, and r=-0.719, p=0.044).
Conclusion: Serum ARE activity is reduced in ACS patients and inversely correlated with inflammatory markers.
Description
Keywords
C-reactive protein, Low-density-lipoprotein, Acute-phase response, Paraoxonase activity, Myocardial-infarction, Unstable angina, Atherosclerosis, Oxidation, Plasma, Mice, General & internal medicine
Citation
Şentürk, T. vd. (2009). "Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes". Saudi Medical Journal, 30(3), 334-339.